Verismo Therapeutics Presents Preclinical Data at SITC 2026 Demonstrating Enhanced Tumor Control and Reduced Cytokine Release with SynKIR™-110 KIR-CAR Compared to Conventional CAR T

The Quick Take
SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells and...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
Business owners brace for threefold squeeze following RBA rate hike - Mortgage Professional America
Business owners brace for threefold squeeze following RBA rate hike Mortgage Professional America
Business
David Koch: Rate hike pain will force tough decisions for small business - SmartCompany
David Koch: Rate hike pain will force tough decisions for small business SmartCompany
Business
Australia services sector PMI contracts for first time in five months
Business
